文献速递慢性肾脏病肾血管病与高血压

循环ADAMs与慢性肾脏病患者的肾脏和心血管结局相关

Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

本研究为观察性多中心研究,纳入2570例CKD 3-5期、5D期患者及无心血管疾病史的对照,检测循环ADAM活性。结果显示晚期CKD患者ADAM活性更高,高ADAM活性是男性CKD进展的独立危险因素,也是心血管事件的独立危险因素。

要点

  • 晚期CKD患者循环ADAM活性高于中度CKD或对照组
  • 男性CKD患者中,高ADAM活性与肾病进展风险独立相关
  • 高ADAM活性是CKD患者心血管事件的独立危险因素

核心结论

  • 高ADAM活性水平与男性CKD患者肾病进展独立相关,并与CKD患者心血管事件独立相关。

研究设计与样本

  • 观察性多中心研究,纳入2570例CKD 3-5期、CKD 5D期患者及无心血管疾病史的对照。
  • 采用荧光技术评估循环ADAM活性,肾脏病进展定义为随访24个月血清肌酐增加30%或需要透析。
  • 心血管结局于随访48个月后评估。

主要发现

  • 晚期CKD患者ADAM活性高于中度CKD患者或对照组。
  • 男性CKD进展患者基线ADAM水平较高:22.19相对荧光单位/μL/h(95%CI 11.22-37.32)vs 12.15(7.02-21.50)。
  • 多因素校正后,男性高ADAM活性与肌酐增加30%相关(OR 2.72,95%CI 1.58-4.68,P<0.001)。
  • 多因素校正后,男性高ADAM活性与需要透析相关(OR 3.00,95%CI 1.65-5.46,P<0.001)。
  • 多因素校正后,男性高ADAM活性与需要透析或肌酐增加30%相关(OR 3.15,95%CI 2.06-4.81,P<0.001)。

临床怎么用

  • 在男性CKD患者中,检测循环ADAM活性可能有助于识别肾病进展和心血管事件高风险者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A disintegrin and metalloproteinase (ADAM) 17, also known as tumour necrosis factor α-converting enzyme (TACE), is a metalloproteinase that releases the ectodomains of most growth factors, cytokines, receptors and enzymes and has been associated with the presence of chronic kidney disease (CKD) and cardiovascular (CV) disease. The role of circulating ADAMs in the progression of renal function and CV events in CKD patients is unknown. METHODS: A total of 2570 subjects from an observational and multicentre study with CKD Stages 3-5, CKD Stage 5D and controls without any history of CV disease were studied. Circulating ADAM activity was assessed using a fluorometric technique. Progression of renal disease was defined as a 30% increase in serum creatinine or dialysis requirement after 24 months of follow-up. CV outcomes were assessed after 48 months of follow-up. RESULTS: Patients with advanced CKD had higher ADAM activity as compared with patients with moderate CKD or controls. Male patients with progression of CKD had higher ADAM levels at baseline compared with patients with stable renal function {22.19 relative fluorescence units/μL/h [95% confidence interval (CI) 11.22-37.32] versus 12.15 (7.02-21.50)}. After multivariate adjustment, higher ADAM activity was identified as a risk factor for progression of CKD in male patients [30% increase in the creatinine odds ratio (OR) 2.72 (95% CI 1.58-4.68), P < 0.001; dialysis requirement OR 3.00 (95% CI 1.65-5.46), P < 0.001; dialysis requirement or 30% increase in the creatinine OR 3.15 (95% CI 2.06-4.81), P < 0.001]. ADAM activity was also identified as an independent risk factor for CV events [hazard ratio (HR) 1.68 (95% CI 1.20-2.36), P = 0.003]. CONCLUSIONS: High ADAMs activity levels are independently associated with CKD progression in males and with CV events in CKD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Palau V, Riera M, Duran X, et al. Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2020. PMID: 30102333. doi:10.1093/ndt/gfy240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。